Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on ESPR. Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $2.15 on Tuesday. The firm has a market cap of $423.64 million, a price-to-earnings ratio of -3.36 and a beta of 0.96. The firm has a fifty day moving average price of $1.97 and a 200 day moving average price of $2.14. Esperion Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $3.40.

Hedge Funds Weigh In On Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in ESPR. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $26,000. Traphagen Investment Advisors LLC purchased a new position in Esperion Therapeutics in the third quarter valued at approximately $27,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics during the second quarter worth approximately $28,000. Sivia Capital Partners LLC purchased a new position in shares of Esperion Therapeutics during the second quarter worth approximately $44,000. Finally, National Bank of Canada FI grew its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.